$PIRS
Pieris Pharmaceuticals Inc Stock $pirs

$pirs Overview Financials Valuation SEC Filings Company Website

2019 Q4 Form 10-K Financial Statement

#000158364821000005 Filed on March 31, 2021

Income Statement

Concept	2019 Q4	2019	2018 Q4
Revenue	$17.27M	$46.28M	$4.910M
YoY Change	251.73%	59.03%	-72.95%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$4.480M	$18.44M	$4.560M
YoY Change	-1.75%	0.0%	-28.64%
% of Gross Profit
Research & Development	$14.12M	$55.00M	$13.00M
YoY Change	8.62%	32.55%	146.68%
% of Gross Profit
Depreciation & Amortization	$260.0K	$600.0K	$160.0K
YoY Change	62.5%	5.26%	60.0%
% of Gross Profit
Operating Expenses	$18.60M	$73.44M	$17.56M
YoY Change	5.92%	22.53%	50.6%
Operating Profit		-$27.16M
YoY Change		-11.92%
Interest Expense	$380.0K	$1.714M	$470.0K
YoY Change	-19.15%	-12.64%	213.33%
% of Operating Profit
Other Income/Expense, Net	$180.0K	-$26.00K	$330.0K
YoY Change	-45.45%	-101.44%	-66.67%
Pretax Income	-$770.0K	-$25.47M	-$11.85M
YoY Change	-93.5%	-5.9%	-255.31%
Income Tax	$0.00	$0.00	-$160.0K
% Of Pretax Income
Net Earnings	-$770.0K	-$25.50M	-$11.68M
YoY Change	-93.41%	-4.69%	-255.94%
Net Earnings / Revenue	-4.46%	-55.1%	-237.88%
Basic Earnings Per Share
Diluted Earnings Per Share	-$14.50K	-$503.1K	-$215.7K
COMMON SHARES
Basic Shares Outstanding	54.98M shares		54.15M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2019 Q4	2019	2018 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$104.2M	$104.2M	$128.1M
YoY Change	-18.66%	-18.66%	76.45%
Cash & Equivalents	$62.26M	$62.30M	$74.87M
Short-Term Investments	$41.90M	$41.90M	$53.20M
Other Short-Term Assets	$4.100M	$4.100M	$4.600M
YoY Change	-10.87%	-10.87%	187.5%
Inventory
Prepaid Expenses
Receivables	$6.787M	$6.800M	$2.701M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$115.0M	$115.0M	$135.4M
YoY Change	-15.05%	-15.07%	50.78%
LONG-TERM ASSETS
Property, Plant & Equipment	$19.50M	$22.90M	$5.049M
YoY Change	286.25%	358.0%	25.16%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments			$0.00
YoY Change			-100.0%
Other Assets	$3.146M	$3.100M	$910.0K
YoY Change	245.71%	244.44%	600.0%
Total Long-Term Assets	$26.08M	$26.10M	$5.959M
YoY Change	337.72%	342.37%	-57.7%
TOTAL ASSETS
Total Short-Term Assets	$115.0M	$115.0M	$135.4M
Total Long-Term Assets	$26.08M	$26.10M	$5.959M
Total Assets	$141.1M	$141.1M	$141.3M
YoY Change	-0.17%	-0.14%	36.07%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$5.803M	$5.800M	$3.350M
YoY Change	73.22%	70.59%	36.62%
Accrued Expenses	$9.944M	$9.500M	$9.114M
YoY Change	9.11%	15.85%	47.71%
Deferred Revenue	$11.26M		$35.61M
YoY Change	-68.39%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$27.00M	$27.00M	$48.08M
YoY Change	-43.83%	-43.87%	5.03%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$0.00	$62.70M	$27.00K
YoY Change	-100.0%	17.64%	-27.03%
Total Long-Term Liabilities	$0.00	$62.70M	$27.00K
YoY Change	-100.0%	17.64%	-27.03%
TOTAL LIABILITIES
Total Short-Term Liabilities	$27.00M	$27.00M	$48.08M
Total Long-Term Liabilities	$0.00	$62.70M	$27.00K
Total Liabilities	$89.75M	$89.70M	$101.4M
YoY Change	-11.5%	-11.54%	9.8%
SHAREHOLDERS EQUITY
Retained Earnings	-$174.2M		-$147.1M
YoY Change	18.43%		22.24%
Common Stock	$227.5M		$190.0M
YoY Change	19.76%		39.15%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$51.35M	$51.40M	$39.94M
YoY Change
Total Liabilities & Shareholders Equity	$141.1M	$141.1M	$141.3M
YoY Change	-0.17%	-0.14%	36.07%

Cashflow Statement

Concept	2019 Q4	2019	2018 Q4
OPERATING ACTIVITIES
Net Income	-$770.0K	-$25.50M	-$11.68M
YoY Change	-93.41%	-4.69%	-255.94%
Depreciation, Depletion And Amortization	$260.0K	$600.0K	$160.0K
YoY Change	62.5%	5.26%	60.0%
Cash From Operating Activities	-$13.98M	-$52.47M	-$9.060M
YoY Change	54.3%	4821.86%	92.77%
INVESTING ACTIVITIES
Capital Expenditures	-$1.170M	$2.462M	-$570.0K
YoY Change	105.26%	44.99%	-29.63%
Acquisitions
YoY Change
Other Investing Activities	-$710.0K	$12.30M	-$4.650M
YoY Change	-84.73%	-271.31%	-89.42%
Cash From Investing Activities	-$1.880M	$9.838M	-$5.220M
YoY Change	-63.98%	-210.85%	-88.34%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	31.67M	$32.17M	10.00K
YoY Change	316600.0%	-33.69%	-98.33%
NET CHANGE
Cash From Operating Activities	-13.98M	-$52.47M	-9.060M
Cash From Investing Activities	-1.880M	$9.838M	-5.220M
Cash From Financing Activities	31.67M	$32.17M	10.00K
Net Change In Cash	15.81M	-$12.61M	-14.27M
YoY Change	-210.79%	-134.08%	-70.79%
FREE CASH FLOW
Cash From Operating Activities	-$13.98M	-$52.47M	-$9.060M
Capital Expenditures	-$1.170M	$2.462M	-$570.0K
Free Cash Flow	-$12.81M	-$54.93M	-$8.490M
YoY Change	50.88%	1887.3%	118.25%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2020	dei	Amendment Flag AmendmentFlag	false
CY2020	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2020
CY2020	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2020	dei	Entity Central Index Key EntityCentralIndexKey	0001583648
CY2018	us-gaap	Accounting Standards Update Extensible List AccountingStandardsUpdateExtensibleList	us-gaap:AccountingStandardsUpdate201409Member
CY2020Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	us-gaap:AccountsPayableAndOtherAccuredLiabilitiesCurrent
CY2019Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	us-gaap:AccountsPayableAndOtherAccuredLiabilitiesCurrent
CY2020	dei	Document Type DocumentType	10-K
CY2020	dei	Document Annual Report DocumentAnnualReport	true
CY2020	dei	Document Period End Date DocumentPeriodEndDate	2020-12-31
CY2020	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2020	dei	Document Transition Report DocumentTransitionReport	false
CY2020	dei	Entity File Number EntityFileNumber	001-37471
CY2020	dei	Entity Registrant Name EntityRegistrantName	PIERIS PHARMACEUTICALS, INC.
CY2020	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NV
CY2020	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	30-0784346
CY2020	dei	Entity Address Address Line1 EntityAddressAddressLine1	255 State Street
CY2020	dei	Entity Address Address Line2 EntityAddressAddressLine2	9th Floor
CY2020	dei	Entity Address City Or Town EntityAddressCityOrTown	Boston
CY2020	dei	Entity Address State Or Province EntityAddressStateOrProvince	MA
CY2020	dei	Entity Address Country EntityAddressCountry	US
CY2020	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	2109
CY2020	dei	City Area Code CityAreaCode	857
CY2020	dei	Local Phone Number LocalPhoneNumber	246-8998
CY2020	dei	Security12b Title Security12bTitle	Common Stock, par value $0.001 per share
CY2020	dei	Trading Symbol TradingSymbol	PIRS
CY2020	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2020	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2020	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2020	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2020	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2020	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2020	dei	Entity Small Business EntitySmallBusiness	true
CY2020	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2020	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2020	dei	Entity Shell Company EntityShellCompany	false
CY2020Q2	dei	Entity Public Float EntityPublicFloat	117421871	USD
CY2021Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	59718989	shares
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	70436000	USD
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	62260000	USD
CY2020Q4	us-gaap	Short Term Investments ShortTermInvestments	0	USD
CY2019Q4	us-gaap	Short Term Investments ShortTermInvestments	41894000	USD
CY2020Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1706000	USD
CY2019Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	6787000	USD
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3579000	USD
CY2019Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	4072000	USD
CY2020Q4	us-gaap	Assets Current AssetsCurrent	75721000	USD
CY2019Q4	us-gaap	Assets Current AssetsCurrent	115013000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	22046000	USD
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	19502000	USD
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	3934000	USD
CY2019Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	3436000	USD
CY2020Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	3309000	USD
CY2019Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	3146000	USD
CY2020Q4	us-gaap	Assets Assets	105010000	USD
CY2019Q4	us-gaap	Assets Assets	141097000	USD
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1787000	USD
CY2019Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	5803000	USD
CY2020Q4	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	7731000	USD
CY2019Q4	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	9944000	USD
CY2020Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	12627000	USD
CY2019Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	11256000	USD
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	22145000	USD
CY2019Q4	us-gaap	Liabilities Current LiabilitiesCurrent	27003000	USD
CY2020Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	35900000	USD
CY2019Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	47258000	USD
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	15932000	USD
CY2019Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	15484000	USD
CY2020Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	6000	USD
CY2019Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	0	USD
CY2020Q4	us-gaap	Liabilities Liabilities	73983000	USD
CY2019Q4	us-gaap	Liabilities Liabilities	89745000	USD
CY2019Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2020Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2020Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2019Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2020Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	14429	shares
CY2020Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	14429	shares
CY2019Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	11429	shares
CY2019Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	11429	shares
CY2020Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2019Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2019Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2019Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	56002815	shares
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	56002815	shares
CY2019Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	55212437	shares
CY2019Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	55212437	shares
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	56000	USD
CY2019Q4	us-gaap	Common Stock Value CommonStockValue	55000	USD
CY2020Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	242672000	USD
CY2019Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	227468000	USD
CY2020Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-295000	USD
CY2019Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-1995000	USD
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-211406000	USD
CY2019Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-174176000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	31027000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	51352000	USD
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	105010000	USD
CY2019Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	141097000	USD
CY2020	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	23911000	USD
CY2019	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	32065000	USD
CY2020	us-gaap	Revenue Not From Contract With Customer RevenueNotFromContractWithCustomer	5412000	USD
CY2019	us-gaap	Revenue Not From Contract With Customer RevenueNotFromContractWithCustomer	14214000	USD
CY2020	us-gaap	Revenues Revenues	29323000	USD
CY2019	us-gaap	Revenues Revenues	46279000	USD
CY2020	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	46531000	USD
CY2019	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	54996000	USD
CY2020	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	16713000	USD
CY2019	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	18440000	USD
CY2020	us-gaap	Operating Expenses OperatingExpenses	63244000	USD
CY2019	us-gaap	Operating Expenses OperatingExpenses	73436000	USD
CY2020	us-gaap	Operating Income Loss OperatingIncomeLoss	-33921000	USD
CY2019	us-gaap	Operating Income Loss OperatingIncomeLoss	-27157000	USD
CY2020	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	511000	USD
CY2019	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	1714000	USD
CY2020	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-3656000	USD
CY2019	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-26000	USD
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-37066000	USD
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-25469000	USD
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	164000	USD
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-37230000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-25469000	USD
CY2020	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	1630000	USD
CY2019	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	973000	USD
CY2020	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	70000	USD
CY2019	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	14000	USD
CY2020	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-35530000	USD
CY2019	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-24482000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-37230000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-25469000	USD
CY2020	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-37230000	USD
CY2019	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-28299000	USD
CY2020	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.68
CY2019	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.56
CY2020	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	54481000	shares
CY2019	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	50625000	shares
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	39935000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-25469000	USD
CY2019	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	973000	USD
CY2019	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	14000	USD
CY2019	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	5374000	USD
CY2019	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	553000	USD
CY2019	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	369000	USD
CY2019	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	246000	USD
CY2019	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	1000000.0	USD
CY2019	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	30998000	USD
CY2019	pirs	Stock Issued During Period Value Conversionof Preferred Stock StockIssuedDuringPeriodValueConversionofPreferredStock	0	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	51352000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-37230000	USD
CY2020	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	1630000	USD
CY2020	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	70000	USD
CY2020	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	5090000	USD
CY2020	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	291000	USD
CY2020	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	200000	USD
CY2020	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	400000	USD
CY2020	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	9624000	USD
CY2020	pirs	Stock Issued During Period Value Conversionof Preferred Stock StockIssuedDuringPeriodValueConversionofPreferredStock	0	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	31027000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-37230000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-25469000	USD
CY2020	us-gaap	Other Depreciation And Amortization OtherDepreciationAndAmortization	2311000	USD
CY2019	us-gaap	Other Depreciation And Amortization OtherDepreciationAndAmortization	632000	USD
CY2020	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	-184000	USD
CY2019	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	408000	USD
CY2020	us-gaap	Share Based Compensation ShareBasedCompensation	5090000	USD
CY2019	us-gaap	Share Based Compensation ShareBasedCompensation	5374000	USD
CY2020	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	133000	USD
CY2020	us-gaap	Marketable Securities Realized Gain Loss Excluding Other Than Temporary Impairments MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments	-471000	USD
CY2019	us-gaap	Marketable Securities Realized Gain Loss Excluding Other Than Temporary Impairments MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments	1161000	USD
CY2020	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	164000	USD
CY2019	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	69000	USD
CY2019	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	0	USD
CY2020	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	8000	USD
CY2019	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	61000	USD
CY2020	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-5343000	USD
CY2019	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	4055000	USD
CY2020	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	500000	USD
CY2019	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	679000	USD
CY2020	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-14496000	USD
CY2019	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-28524000	USD
CY2020	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	-4354000	USD
CY2019	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	1257000	USD
CY2020	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-1655000	USD
CY2019	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-914000	USD
CY2020	pirs	Increase Decreasein Operating Lease Liabilities IncreaseDecreaseinOperatingLeaseLiabilities	715000	USD
CY2019	pirs	Increase Decreasein Operating Lease Liabilities IncreaseDecreaseinOperatingLeaseLiabilities	-794000	USD
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-45896000	USD
CY2019	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-52467000	USD
CY2020	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2726000	USD
CY2019	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2462000	USD
CY2020	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	83437000	USD
CY2019	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	63325000	USD
CY2020	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	0	USD
CY2019	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	8292000	USD
CY2020	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	41499000	USD
CY2019	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	59317000	USD
CY2020	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	39212000	USD
CY2019	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	9838000	USD
CY2020	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	291000	USD
CY2019	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	553000	USD
CY2020	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	200000	USD
CY2019	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	369000	USD
CY2020	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	0	USD
CY2019	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	246000	USD
CY2020	pirs	Proceeds From Issuance Of Common And Preferred Stock ProceedsFromIssuanceOfCommonAndPreferredStock	9624000	USD
CY2019	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	32166000	USD
CY2019	pirs	Proceeds From Issuance Of Common And Preferred Stock ProceedsFromIssuanceOfCommonAndPreferredStock	30998000	USD
CY2020	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	10115000	USD
CY2020	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	4745000	USD
CY2019	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-2144000	USD
CY2020	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	8176000	USD
CY2019	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-12607000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	62260000	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	74867000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	70436000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	62260000	USD
CY2020	pirs	Accretionof Convertible Preferred Stock AccretionofConvertiblePreferredStock	0	USD
CY2019	pirs	Accretionof Convertible Preferred Stock AccretionofConvertiblePreferredStock	2830000	USD
CY2020	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	70000	USD
CY2019	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	0	USD
CY2020	pirs	Property And Equipment Included In Accounts Payable PropertyAndEquipmentIncludedInAccountsPayable	131000	USD
CY2019	pirs	Property And Equipment Included In Accounts Payable PropertyAndEquipmentIncludedInAccountsPayable	1235000	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	70400000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-37200000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-25500000	USD
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-211400000	USD
CY2020	us-gaap	Use Of Estimates UseOfEstimates	The preparation of the financial statements in accordance with U.S. GAAP requires management to make estimates, judgments, and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses and the related disclosures at the date of the financial statements and during the reporting period. Significant estimates are used for, but are not limited to, assumptions used to estimate its ability to continue as a going concern; revenue recognition; deferred tax assets, deferred tax liabilities and valuation allowances; beneficial conversion features; fair value of stock options, preferred stock, and warrants; and various accruals. Management evaluates its estimates on an ongoing basis. Actual results and outcomes could differ materially from management’s estimates, judgments, and assumptions.
CY2020	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Concentration of Credit Risk and Off-Balance Sheet Risk</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has no financial instruments with off‑balance sheet risk such as foreign exchange contracts, option contracts, or other foreign hedging arrangements. Financial instruments that subject Pieris to concentrations of credit risk include cash and cash equivalents, investments, and accounts receivable. The Company’s cash, cash equivalents, and investments are held in accounts with financial institutions that management believes are creditworthy. The Company’s investment policy includes guidelines on the quality of the institutions and financial instruments and defines allowable investments that the Company </span></div>believes minimizes the exposure to concentration of credit risk. The Company has not experienced any credit losses in such accounts and does not believe it is exposed to any significant credit risk on these funds. Accounts receivable primarily consist of amounts due under strategic partnership and other license agreements with major multi-national pharmaceutical companies for which the Company does not obtain collateral.
CY2020Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	0	USD
CY2019Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	0	USD
CY2019	us-gaap	Revenues Revenues	46279000	USD
CY2020	us-gaap	Revenues Revenues	29323000	USD
CY2019	us-gaap	Revenues Revenues	46279000	USD
CY2017Q2	pirs	Number Of Technology Licenses NumberOfTechnologyLicenses	5	leaseAgreement
CY2017Q1	pirs	Number Of Separate Performance Obligations NumberOfSeparatePerformanceObligations	1	performanceObligation
CY2020	pirs	Additionsto Contractwith Customer Liability AdditionstoContractwithCustomerLiability	1600000	USD
CY2020	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	15000000.0	USD
CY2020Q4	pirs	Cash Equivalents And Investments CashEquivalentsAndInvestments	63951000	USD
CY2019Q4	pirs	Cash Equivalents And Investments CashEquivalentsAndInvestments	89278000	USD
CY2019Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	41964000	USD
CY2019Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	57000	USD
CY2020Q4	pirs	Accrued Tax Audit And Legal Fees AccruedTaxAuditAndLegalFees	128000	USD
CY2019Q4	pirs	Accrued Tax Audit And Legal Fees AccruedTaxAuditAndLegalFees	522000	USD
CY2019Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	127000	USD
CY2019Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	41894000	USD
CY2020	us-gaap	Debt Securities Available For Sale Realized Gain Loss DebtSecuritiesAvailableForSaleRealizedGainLoss	-600000	USD
CY2019	us-gaap	Debt Securities Available For Sale Realized Gain Loss DebtSecuritiesAvailableForSaleRealizedGainLoss	300000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	27861000	USD
CY2019Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	23069000	USD
CY2020Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	5815000	USD
CY2019Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	3567000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	22046000	USD
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	19502000	USD
CY2020	us-gaap	Depreciation Depreciation	2100000	USD
CY2019	us-gaap	Depreciation Depreciation	600000	USD
CY2020	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	USD
CY2020Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	2759000	USD
CY2019Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	2870000	USD
CY2020Q4	pirs	Accrued Research And Development Costs AccruedResearchAndDevelopmentCosts	2001000	USD
CY2019Q4	pirs	Accrued Research And Development Costs AccruedResearchAndDevelopmentCosts	1048000	USD
CY2020Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1220000	USD
CY2019Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	4251000	USD
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1030000	USD
CY2019Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	733000	USD
CY2020Q4	pirs	Accrued License Obligations AccruedLicenseObligations	358000	USD
CY2019Q4	pirs	Accrued License Obligations AccruedLicenseObligations	62000	USD
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.008
CY2020Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	235000	USD
CY2019Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	458000	USD
CY2020Q4	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	7731000	USD
CY2019Q4	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	9944000	USD
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-12134000	USD
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-12063000	USD
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-24932000	USD
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-13406000	USD
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-37066000	USD
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-25469000	USD
CY2019	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	0	USD
CY2020	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	164000	USD
CY2019	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	USD
CY2020	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	0	USD
CY2019	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	0	USD
CY2020	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	164000	USD
CY2019	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	0	USD
CY2020	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	0	USD
CY2019	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	0	USD
CY2020	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	0	USD
CY2019	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	0	USD
CY2020	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	0	USD
CY2019	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	0	USD
CY2020	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	USD
CY2019	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	USD
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	164000	USD
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2019Q4	pirs	Deferred Tax Assets Depreciationand Other DeferredTaxAssetsDepreciationandOther	53000	USD
CY2020	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2019	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	0.019
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	0.019
CY2020	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.019
CY2019	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.026
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Repatriation Of Foreign Earnings EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings	0
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Repatriation Of Foreign Earnings EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings	-0.012
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	-0.038
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	-0.025
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	-0.024
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	-0.010
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.004
CY2020Q4	pirs	Deferred Tax Assets Depreciationand Other DeferredTaxAssetsDepreciationandOther	297000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Unrealized Currency Losses DeferredTaxAssetsUnrealizedCurrencyLosses	771000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Unrealized Currency Losses DeferredTaxAssetsUnrealizedCurrencyLosses	90000	USD
CY2020Q4	pirs	Deferred Tax Asset Lease Liability DeferredTaxAssetLeaseLiability	4582000	USD
CY2020	pirs	Effective Income Tax Rate Reconciliation Rate Change Dueto Trade Taxon Net Operating Loss Percent EffectiveIncomeTaxRateReconciliationRateChangeDuetoTradeTaxonNetOperatingLossPercent	0
CY2019	pirs	Effective Income Tax Rate Reconciliation Rate Change Dueto Trade Taxon Net Operating Loss Percent EffectiveIncomeTaxRateReconciliationRateChangeDuetoTradeTaxonNetOperatingLossPercent	-0.064
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.187
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.152
CY2020	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.005
CY2019	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
CY2020Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	39175000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	30455000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits	2913000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits	2705000	USD
CY2020Q4	pirs	Deferred Tax Assets Accrued Compensation And Other DeferredTaxAssetsAccruedCompensationAndOther	230000	USD
CY2019Q4	pirs	Deferred Tax Assets Accrued Compensation And Other DeferredTaxAssetsAccruedCompensationAndOther	328000	USD
CY2019Q4	pirs	Deferred Tax Asset Lease Liability DeferredTaxAssetLeaseLiability	4378000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	47968000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	38009000	USD
CY2020Q4	pirs	Deferred Tax Liabilities Lease Rightof Use Asset DeferredTaxLiabilitiesLeaseRightofUseAsset	4235000	USD
CY2019Q4	pirs	Deferred Tax Liabilities Lease Rightof Use Asset DeferredTaxLiabilitiesLeaseRightofUseAsset	4043000	USD
CY2020Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	4235000	USD
CY2019Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	4043000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	43733000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	33966000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	USD
CY2019Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	USD
CY2020	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	-9800000	USD
CY2020Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0	USD
CY2019Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0	USD
CY2019Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	6032000	USD
CY2020	us-gaap	Stock Issued During Period Shares Employee Stock Purchase Plans StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans	69544	shares
CY2020	us-gaap	Unrecognized Tax Benefits Increases Resulting From Foreign Currency Translation UnrecognizedTaxBenefitsIncreasesResultingFromForeignCurrencyTranslation	103000	USD
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	6135000	USD
CY2016Q2	us-gaap	Stock Issued During Period Shares Conversion Of Units StockIssuedDuringPeriodSharesConversionOfUnits	1	shares
CY2016Q2	pirs	Warrant Exercisable Period WarrantExercisablePeriod	P5Y
CY2019Q3	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	50000000.0	USD
CY2020	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	37000000.0	shares
CY2019	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	33400000	shares
CY2019	us-gaap	Stock Issued During Period Shares Employee Stock Purchase Plans StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans	113112	shares
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0010
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0018
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.7436
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	1.2089
CY2020	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	5090000	USD
CY2019	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	5374000	USD
CY2020Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	7100000	USD
CY2020	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y1M20D
CY2020	us-gaap	Operating Lease Cost OperatingLeaseCost	1509000	USD
CY2019	us-gaap	Operating Lease Cost OperatingLeaseCost	1524000	USD
CY2020	us-gaap	Variable Lease Cost VariableLeaseCost	708000	USD
CY2019	us-gaap	Variable Lease Cost VariableLeaseCost	293000	USD
CY2020	us-gaap	Lease Cost LeaseCost	2217000	USD
CY2019	us-gaap	Lease Cost LeaseCost	1817000	USD
CY2020Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P11Y4M24D
CY2019Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P12Y1M6D
CY2020Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.105
CY2019Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.105
CY2020	us-gaap	Operating Lease Payments OperatingLeasePayments	2200000	USD
CY2019	us-gaap	Operating Lease Payments OperatingLeasePayments	500000	USD
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	2662000	USD
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	2458000	USD
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	2424000	USD
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	2424000	USD
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	2424000	USD
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	14556000	USD
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	26948000	USD
CY2020Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	9986000	USD
CY2020Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	16962000	USD

Files In Submission

Name	View Source	Status
0001583648-21-000005-index-headers.html	Edgar Link	pending
0001583648-21-000005-index.html	Edgar Link	pending
0001583648-21-000005.txt	Edgar Link	pending
0001583648-21-000005-xbrl.zip	Edgar Link	pending
a210317pirsethicsandwhis.htm	Edgar Link	pending
a210317pirsethicsandwhis001.jpg	Edgar Link	pending
a210317pirsethicsandwhis002.jpg	Edgar Link	pending
a210317pirsethicsandwhis003.jpg	Edgar Link	pending
a210317pirsethicsandwhis004.jpg	Edgar Link	pending
a210317pirsethicsandwhis005.jpg	Edgar Link	pending
a210317pirsethicsandwhis006.jpg	Edgar Link	pending
a210317pirsethicsandwhis007.jpg	Edgar Link	pending
a210317pirsethicsandwhis008.jpg	Edgar Link	pending
a210317pirsethicsandwhis009.jpg	Edgar Link	pending
a210317pirsethicsandwhis010.jpg	Edgar Link	pending
a210317pirsethicsandwhis011.jpg	Edgar Link	pending
a210317pirsethicsandwhis012.jpg	Edgar Link	pending
a210317pirsethicsandwhis013.jpg	Edgar Link	pending
a210317pirsethicsandwhis014.jpg	Edgar Link	pending
a210317pirsethicsandwhis015.jpg	Edgar Link	pending
a210317pirsethicsandwhis016.jpg	Edgar Link	pending
a210317pirsethicsandwhis017.jpg	Edgar Link	pending
a210317pirsethicsandwhis018.jpg	Edgar Link	pending
a210317pirsethicsandwhis019.jpg	Edgar Link	pending
a210317pirsethicsandwhis020.jpg	Edgar Link	pending
a210317pirsethicsandwhis021.jpg	Edgar Link	pending
a210317pirsethicsandwhis022.jpg	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
pirs-20201231.htm	Edgar Link	pending
pirs-20201231.xsd	Edgar Link	pending
pirs-20201231_cal.xml	Edgar Link	unprocessable
pirs-20201231_def.xml	Edgar Link	unprocessable
pirs-20201231_g1.jpg	Edgar Link	pending
pirs-20201231_g10.jpg	Edgar Link	pending
pirs-20201231_g11.jpg	Edgar Link	pending
pirs-20201231_g12.jpg	Edgar Link	pending
pirs-20201231_g13.jpg	Edgar Link	pending
pirs-20201231_g2.jpg	Edgar Link	pending
pirs-20201231_g3.jpg	Edgar Link	pending
pirs-20201231_g4.jpg	Edgar Link	pending
pirs-20201231_g5.jpg	Edgar Link	pending
pirs-20201231_g6.jpg	Edgar Link	pending
pirs-20201231_g7.jpg	Edgar Link	pending
pirs-20201231_g8.jpg	Edgar Link	pending
pirs-20201231_g9.jpg	Edgar Link	pending
pirs-20201231_htm.xml	Edgar Link	completed
pirs-20201231_lab.xml	Edgar Link	unprocessable
pirs-20201231_pre.xml	Edgar Link	unprocessable
pirs12312020ex211.htm	Edgar Link	pending
pirs12312020ex231.htm	Edgar Link	pending
pirs12312020ex311.htm	Edgar Link	pending
pirs12312020ex312.htm	Edgar Link	pending
pirs12312020ex321.htm	Edgar Link	pending
pirs12312020ex322.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R9999.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$PIRS
Pieris Pharmaceuticals Inc Stock $pirs

2019 Q4 Form 10-K Financial Statement

#000158364821000005 Filed on March 31, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PIRS Pieris Pharmaceuticals Inc Stock $pirs

2019 Q4 Form 10-K Financial Statement

#000158364821000005 Filed on March 31, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PIRS
Pieris Pharmaceuticals Inc Stock $pirs